3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neoplasms
4
Neoplasm Metastasis
3
Lung Neoplasms
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Solid Tumors
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Rare Tumour
1
Rare Tumor
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasms by Site
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Genomic Instability
1
Interventions
Cyclophosphamide
33
fludarabine phosphate
19
Peripheral Blood Stem Cell Transplantation
19
Mycophenolic Acid
17
Whole-Body Irradiation
15
Etoposide
15
Rituximab
14
Tacrolimus
13
Busulfan
12
Vincristine
11
Prednisone
11
Methotrexate
11
Filgrastim
11
Doxorubicin
11
Cyclosporine
11
Radiotherapy
10
Brentuximab Vedotin
10
Antilymphocyte Serum
10
Methylprednisolone
8
Cytarabine
8
Melphalan
7
Cisplatin
6
Ifosfamide
5
Gemcitabine
5
merphos
4
ibritumomab tiuxetan
4
Sirolimus
4
Flow Cytometry
4
Dexamethasone
4
Cyclosporins
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, Large-Cell, Anaplastic
×
alectinib
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts